VivoSeq
Immunology

Allergic Conjunctivitis

62

Pipeline Programs↗

4

Active Trials↗

34

Companies Involved↗

Allergic Conjunctivitis is a moderately active landscape with 62 programs across 34 companies. The most active players are Aldeyra Therapeutics, Inc., Fovea Pharmaceuticals SA, Telios Pharma, Inc.. 19 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

15/100

Mech. Concentration

40/100

Completion Rate

94/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aldeyra Therapeutics, Inc.

3 programs

Phase 2F

Fovea Pharmaceuticals SA

2 programs

Phase 2T

Telios Pharma, Inc.

1 program

Phase 2N

Noveome Biotherapeutics, formerly Stemnion

1 program

Phase 2V

Vanda Pharmaceuticals

1 program

Phase 2Sun Pharma Advanced Research Company Limited logo

Sun Pharma Advanced Research Company Limited

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

89 of 91 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody11%Protein / enzyme11%

Small molecule leads; the ring shows all 91 classified programs, each share of the total. Modality classified for 96% of 96 pipeline programs.

Analysis

Trial Status

89

clinical trials

Completed76 · 85%
Unknown status4 · 4%
Withdrawn3 · 3%
Recruiting3 · 3%
Terminated2 · 2%
Not yet recruiting1 · 1%

Clinical Trials

Trial Activity

89 trials

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Recruiting·TTelios Pharma, Inc.·Phase 2·NCT07220408·60 enrolled
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Recruiting·TTelios Pharma, Inc.·Phase 2·NCT06686472·66 enrolled
A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Bet v 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Birch Pollen Allergy
Recruiting·Regeneron logoRegeneron·Phase 3·NCT07309432·350 enrolled
A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy
Not yet recruiting·Regeneron logoRegeneron·Phase 3·NCT07675811·570 enrolled
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Completed·AbbVie logoAbbVie·Phase 3·NCT02161146·240 enrolled
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
Completed·VVistakon Pharmaceuticals·Phase 3·NCT00364091·365 enrolled
Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects
Completed·AAlcon Research·Phase 3·NCT00987272·267 enrolled
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
Completed·VVistakon Pharmaceuticals·Phase 3·NCT00241319·150 enrolled
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Completed·—·Phase 4·NCT01569191·18 enrolled
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Completed·AAlcon Research·Phase 3·NCT00331500·287 enrolled
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Completed·AAldeyra Therapeutics, Inc.·Phase 3·NCT03494504·318 enrolled
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Completed·SSouthern California College of Optometry at Marshall B. Ketchum University·Phase 4·NCT01443442·23 enrolled
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis
Completed·VVistakon Pharmaceuticals·Phase 3·NCT00432757·120 enrolled
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
Completed·CC.T. Development America, Inc.·Phase 2·NCT01639846·60 enrolled
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
Completed·AAlcon Research·Phase 3·NCT01037179·110 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)